New once-daily HIV drug helps with patient compliance
Emtriva is the first once-daily nucleoside reverse transcriptase inhibitor to receive a nod of approval from the FDA.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Related Content
